Published in BMJ on October 26, 2012
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J (2015) 1.55
The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract (2013) 1.43
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis (2012) 1.08
Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysis. PLoS One (2014) 1.05
Fungal allergy in asthma-state of the art and research needs. Clin Transl Allergy (2014) 1.03
Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother (2013) 0.96
Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS (2014) 0.96
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother (2015) 0.91
Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program. Emerg Infect Dis (2015) 0.89
Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. PLoS One (2016) 0.88
Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine (2013) 0.86
Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. BMC Health Serv Res (2014) 0.82
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. PLoS Med (2015) 0.80
Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. Vaccine (2014) 0.79
The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis (2017) 0.75
Economic studies applied to vaccines against invasive diseases: an updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Hum Vaccin Immunother (2016) 0.75
Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccin Immunother (2016) 0.75
Striking Similarities in the Presentation and Duration of Illness of Influenza A and B in the Community: A Study Based on Sentinel Surveillance Networks in France and Turkey, 2010-2012. PLoS One (2015) 0.75
Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clin Drug Investig (2016) 0.75
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (1996) 10.84
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med (2003) 7.39
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1997) 7.36
Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis (2003) 5.73
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis (2011) 5.31
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax (2001) 3.38
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med (2011) 2.59
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA (2012) 2.42
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr (2010) 2.21
Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect (2009) 1.89
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine (2011) 1.75
Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med (2008) 1.57
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect (2012) 1.43
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis (2010) 1.41
Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine (2004) 1.33
Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect (2005) 1.33
7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS One (2011) 1.16
The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis (2011) 1.14
Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill (2011) 1.11
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther (2010) 1.09
The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect (2010) 1.06
The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol (2002) 1.04
Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med (2000) 1.01
Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines (2011) 0.99
Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med (2008) 13.35
Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis (2005) 5.35
Delaying the international spread of pandemic influenza. PLoS Med (2006) 4.50
Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine (2006) 4.28
Global epidemiology of meningococcal disease. Vaccine (2009) 4.26
Planning for smallpox outbreaks. Nature (2003) 4.16
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet (2009) 4.07
Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol (2003) 3.73
Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis (2002) 3.66
No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis (2006) 3.18
Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract (2007) 3.16
Interim smallpox guidelines for the United Kingdom. BMJ (2002) 3.14
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ (2002) 3.01
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine (2005) 2.81
Initial human transmission dynamics of the pandemic (H1N1) 2009 virus in North America. Influenza Other Respir Viruses (2009) 2.69
Dynamic social networks and the implications for the spread of infectious disease. J R Soc Interface (2008) 2.69
Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine (2010) 2.66
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med (2011) 2.59
Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.56
Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol (2006) 2.46
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (2003) 2.30
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis (2005) 2.29
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. Emerg Infect Dis (2004) 2.16
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol (2013) 2.08
The impact of early behavior disturbances on academic achievement in high school. Pediatrics (2009) 2.03
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis (2009) 2.02
The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine (2009) 1.94
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol (2008) 1.92
Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect (2009) 1.89
Using an online survey of healthcare-seeking behaviour to estimate the magnitude and severity of the 2009 H1N1v influenza epidemic in England. BMC Infect Dis (2011) 1.89
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr (2009) 1.87
Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol (2012) 1.85
Precautionary behavior in response to perceived threat of pandemic influenza. Emerg Infect Dis (2007) 1.84
Social contact patterns in Vietnam and implications for the control of infectious diseases. PLoS One (2011) 1.83
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Measured dynamic social contact patterns explain the spread of H1N1v influenza. PLoS Comput Biol (2012) 1.77
Infectious disease: tough choices to reduce Ebola transmission. Nature (2014) 1.77
Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine (2008) 1.76
Internet-based surveillance of Influenza-like-illness in the UK during the 2009 H1N1 influenza pandemic. BMC Public Health (2010) 1.75
Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med (2013) 1.74
Increasing hospital admissions for pneumonia, England. Emerg Infect Dis (2008) 1.72
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis (2008) 1.65
Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ (2002) 1.63
Wired for wellness: e-interventions for addressing college drinking. J Subst Abuse Treat (2005) 1.61
The burden of Herpes Zoster: a prospective population based study. Vaccine (2005) 1.61
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol (2008) 1.58
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
What types of contacts are important for the spread of infections?: using contact survey data to explore European mixing patterns. Epidemics (2011) 1.56
Evaluation of the benefits and risks of introducing Ebola community care centers, Sierra Leone. Emerg Infect Dis (2015) 1.56
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine (2012) 1.56
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol (2005) 1.52
Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One (2011) 1.52
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics (2004) 1.48
Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England. Dev Med Child Neurol (2014) 1.48
Continence care for obese nursing home residents. Urol Nurs (2010) 1.48
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr (2010) 1.44
Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem (2001) 1.44
Male reproductive control of women who have experienced intimate partner violence in the United States. Soc Sci Med (2010) 1.43
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect (2012) 1.43
The impact of school holidays on the social mixing patterns of school children. Epidemics (2011) 1.43
Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol (2004) 1.41
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis (2010) 1.41
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab (2002) 1.40
The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect (2007) 1.39
Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis (2002) 1.38
Characteristics of natural mentoring relationships from the perspectives of homeless youth. J Child Adolesc Psychiatr Nurs (2013) 1.38
The possible macroeconomic impact on the UK of an influenza pandemic. Health Econ (2010) 1.37
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun (2003) 1.36
Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis (2007) 1.36
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health (2007) 1.36
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin (2012) 1.34
Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. J Urol (2002) 1.33
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol (2004) 1.32
Reproductive coercion: connecting the dots between partner violence and unintended pregnancy. Contraception (2010) 1.31
Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol (2009) 1.30
Modelling the impact of local reactive school closures on critical care provision during an influenza pandemic. Proc Biol Sci (2011) 1.28
The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One (2011) 1.27
Gender-equitable attitudes, bystander behavior, and recent abuse perpetration against heterosexual dating partners of male high school athletes. Am J Public Health (2013) 1.27
Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ (2004) 1.27
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis (2011) 1.25